Evommune, Inc. EVMN shares jumped Tuesday following the announcement of positive top-line results from its Phase 2a trial evaluating EVO301 for treating moderate-to-severe atopic dermatitis. The ...
The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...
Nektar Therapeutics shares rose in premarket trading Tuesday after the company said it received positive data from its dermatitis drug study. Shares traded 13% higher ahead of the morning bell at $42.
New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadershipWill build ...
A variety of potentially life-saving medications are available online, including Insulin Lispro, Farxiga and Tikosyn. There ...
The TrumpRx.gov website helps uninsured & cash-paying patients save on 40+ brand drugs. Here's the complete list of ...
Amgen ends its rocatinlimab partnership, returning control to Kyowa Kirin, citing strategy changes, weaker Phase 3 results ...
Amgen and Kyowa Kirin are pulling the plug on a collaboration the drugmakers launched in 2021 aimed at developing a treatment for the inflammatory skin disease atopic dermatitis.
The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...
TRex Bio banked a Series B extension to advance its atopic dermatitis program, which is competing in a crowded field.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results